S&P 500
7,541.40
-38.67
-0.51%
Dow
51,983.98
+213.67
+0.41%
Nasdaq
25,164.32
-272.68
-1.07%
NYSE Composite
24,372.07
+78.98
+0.33%
Russell 2000
2,805.88
-5.97
-0.21%
VIX
21.15
+1.73
+8.91%
IDXX · IDEXX Laboratories, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
IDEXX Laboratories, Inc. (IDXX)
NASDAQ NMS - GLOBAL MARKET
Health Care
$672.06
+120.58
(+21.86%)
● At close: November 2 at 4:00:00 PM EDT
$675.00
+3.36
(+0.50%)
After-Hours:
5:02:17 PM EDT
DAY'S RANGE
$672.06
$621.14
$673.07
52-WEEK RANGE
$672.06
$500.61
$769.98
What's happening
- IDXX is up 21.86% today, trading at $672.06. — Live quote
- Volume today (102,073) is well below its 3-month average of 577,700. (Finnhub fundamentals)
- Reports earnings on 2026-11-02 (before market open), 0 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $3.98 actual vs. $3.81 estimated (+4.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 8
Hold 7
Sell 0
Strong sell 0
Aggregate ratings for 2026-11-01 (21 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IDXX
-18.52%
vs S&P 500
-29.35%
1-YEAR RETURN
IDXX
-12.30%
vs S&P 500
-23.47%
6-MONTH RETURN
IDXX
-3.01%
3-MONTH RETURN
IDXX
-1.41%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-11-02 (Q3 2026)
$3.98
Est. $3.81
BEAT +4.4%
2026-07-26 (Q2 2026)
$4.27
Est. $4.02
BEAT +6.2%
2026-04-26 (Q1 2026)
$3.47
Est. $3.47
BEAT +0.1%
2026-01-26 (Q4 2025)
$3.08
Est. $2.99
BEAT +3.1%
Valuation Measures & Ratios
Enterprise Value4$44.20B
Forward P/E533.55
PEG Ratio62.83
Price / Sales (TTM1)9.54
Price / Book725.75
EV4 / Revenue9.71
EV4 / EBITDA27.41
Profit Margin25.03%
Operating Margin32.03%
Return on Equity (ROE8)71.96%
Return on Assets (ROA9)33.61%
Avg Volume (3M)577,700
Quarterly history (5 periods)
| Measure | Sep '26 | Jun '26 | Mar '26 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|
| Market cap | $41.31B | $41.71B | $45.08B | $51.61B | $43.47B |
| P/E | 34.18 | 35.18 | 41.37 | 49.43 | 44.69 |
| Price/Sales | 8.83 | 9.12 | 10.35 | 12.32 | 10.64 |
| Price/Book | 22.10 | 25.86 | 28.97 | 33.06 | 29.80 |
| EV/Revenue | 8.87 | 9.18 | 10.41 | 12.40 | 10.73 |
| EV/EBITDA | 24.38 | 25.17 | 29.22 | — | — |
| ROE | 64.66% | 73.51% | 70.03% | 66.88% | 66.68% |
| ROA | 32.60% | 34.44% | 32.19% | 30.83% | 29.21% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,929,268
Change from Prior Settlement-0.59%
% of Float—
Days to Cover (Short Ratio)3.62
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-10-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 9.7% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 25.0%. Finnhub fundamentals ↗
Potential concerns
- Trailing 52-week price return is -12.3%. Finnhub market metrics ↗
- Trailing P/E is 38.1, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-Q, filed 2026-11-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IDXX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Sep '26 | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.22B | $1.14B | $1.11B | $1.11B | $998.4M | $975.5M | $1.00B |
| Gross profit | $764.3M | $779.1M | $722.7M | $683.4M | $694.7M | $623.4M | $596.0M | $619.2M |
| Operating income | $402.3M | $425.6M | $362.6M | $354.8M | $373.0M | $316.5M | $303.9M | $263.8M |
| Net income | $317.1M | $338.4M | $278.4M | $274.6M | $294.0M | $242.7M | $232.8M | $203.3M |
| EPS (diluted) | $4.01 | $4.27 | $3.47 | $3.40 | $3.63 | $2.96 | $2.80 | $2.44 |
| EPS (basic) | $4.02 | $4.29 | $3.50 | $3.43 | $3.66 | $2.98 | $2.83 | $2.46 |
| Operating margin | $33 | $35 | $32 | $32 | $34 | $32 | $31 | $26 |
| Net margin | $26 | $28 | $24 | $25 | $26 | $24 | $24 | $20 |
Balance sheet
| Line item | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $3.71B | $3.44B | $3.39B | $3.35B | $3.39B | $3.33B | $3.21B | $3.29B |
| Total liabilities | $1.84B | $1.83B | $1.83B | $1.75B | $1.83B | $1.87B | $1.77B | $1.70B |
| Stockholders' equity | $1.87B | $1.61B | $1.56B | $1.61B | $1.56B | $1.46B | $1.45B | $1.60B |
| Total current assets | $1.50B | $1.51B | $1.45B | $1.41B | $1.48B | $1.36B | $1.32B | $1.40B |
| Total current liabilities | $1.26B | $1.29B | $1.30B | $1.15B | $1.25B | $1.22B | $1.14B | $1.07B |
| Cash & equivalents | $197.5M | $196.9M | $200.5M | $180.1M | $208.2M | $164.6M | $164.0M | $288.3M |
| Accounts receivable | $615.8M | $627.1M | $603.5M | $552.4M | $566.9M | $560.6M | $527.5M | $473.6M |
| Inventory | $390.9M | $391.6M | $382.4M | $377.8M | $391.6M | $392.6M | $396.0M | $381.9M |
| Other current assets | $295.8M | $293.9M | $267.6M | $303.6M | $310.4M | $244.6M | $230.2M | $256.2M |
| Property, plant & equipment | $732.1M | $733.2M | $740.4M | $747.4M | $739.4M | $739.7M | $717.6M | $713.1M |
| Goodwill | $640.5M | $410.9M | $412.1M | $414.0M | $413.7M | $414.5M | $407.5M | $405.1M |
| Intangible assets | $117.8M | $98.2M | $104.8M | $109.8M | $114.8M | $103.7M | $107.4M | $111.7M |
| Other non-current assets | $596.9M | $567.7M | $552.8M | $542.5M | $513.6M | $580.8M | $547.6M | $547.5M |
| Accounts payable | $154.1M | $129.1M | $130.0M | $110.4M | $122.3M | $116.6M | $120.1M | $114.2M |
| Accrued liabilities | $521.0M | $453.2M | $453.6M | $530.1M | $488.9M | $417.0M | $490.7M | $502.1M |
| Deferred revenue (current) | $40.2M | $36.4M | $36.3M | $35.3M | $35.7M | $36.3M | $35.0M | $33.8M |
| Short-term debt | $75.0M | $150.0M | $150.0M | $75.0M | $150.0M | $75.0M | $170.9M | $167.8M |
| Long-term debt | $299.9M | $299.9M | $299.9M | $374.8M | $374.8M | $449.8M | $449.8M | $449.8M |
| Other non-current liabilities | $82.4M | $56.5M | $54.0M | $56.5M | $57.6M | $56.8M | $47.7M | $44.3M |
| Common stock & paid-in capital | $10.9M | $10.9M | $10.8M | $10.8M | $10.8M | $10.8M | $10.8M | $10.8M |
| Retained earnings | $7.33B | $7.01B | $6.67B | $6.39B | $6.14B | $5.87B | $5.58B | $5.33B |
| Accumulated other comprehensive income (loss) | -$60.5M | -$63.5M | -$64.9M | -$68.8M | -$73.0M | -$77.0M | -$90.1M | -$93.6M |
Cash flow
| Line item | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $449.7M | $347.2M | $266.2M | $355.8M | $402.3M | $185.7M | $238.0M | $262.0M |
| Investing cash flow | -$248.1M | -$25.5M | -$33.5M | -$28.1M | -$44.9M | -$33.6M | -$29.6M | -$39.8M |
| Financing cash flow | -$200.8M | -$325.2M | -$211.4M | -$355.7M | -$313.3M | -$165.6M | -$330.3M | -$232.8M |
| Free cash flow | $420.8M | $322.5M | $234.3M | $326.3M | $371.2M | $151.6M | $207.9M | $232.8M |
| Capital expenditures | $28.9M | $24.6M | $32.0M | $29.4M | $31.1M | $34.1M | $30.0M | $29.3M |
| Depreciation & amortization | $40.6M | $41.1M | $37.7M | $38.7M | $36.6M | $35.8M | $34.1M | $33.7M |
| Share-based compensation | $16.2M | $16.1M | $16.3M | $16.1M | $14.4M | $14.9M | $14.6M | $14.3M |
| Deferred income taxes | — | — | — | $131.2M | — | — | — | $4.7M |
| Change in accounts receivable | -$10.1M | $26.0M | $56.8M | -$13.9M | $7.7M | $29.6M | $45.2M | -$27.8M |
| Change in inventory | -$1.7M | $4.0M | -$2.2M | -$1.4M | -$1.9M | $6.2M | -$2.2M | $3.2M |
| Change in accounts payable | $18.1M | -$6.7M | $11.2M | -$3.6M | $7.1M | -$4.0M | -$8.1M | $5.7M |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | $112.2M | $346.8M | $351.0M | $237.8M | $240.2M | $338.1M | $400.9M | $246.0M |
| Debt issued | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $150.0K | $298.0K | $10.6M | $60.0K | $85.0K | $970.0K | $6.1M | $45.0K |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B |
| Gross profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B |
| Operating income | $1.36B | $1.13B | $1.10B | $898.8M | $932.0M |
| Net income | $1.06B | $887.9M | $845.0M | $679.1M | $744.8M |
| EPS (diluted) | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
| EPS (basic) | $13.17 | $10.77 | $10.17 | $8.12 | $8.74 |
| Operating margin | $32 | $29 | $30 | $27 | $29 |
| Net margin | $25 | $23 | $23 | $20 | $23 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $3.35B | $3.29B | $3.26B | $2.75B | $2.44B |
| Total liabilities | $1.75B | $1.70B | $1.78B | $2.14B | $1.75B |
| Stockholders' equity | $1.61B | $1.60B | $1.48B | $608.7M | $690.0M |
| Total current assets | $1.41B | $1.40B | $1.50B | $1.10B | $955.7M |
| Total current liabilities | $1.15B | $1.07B | $951.5M | $1.24B | $763.6M |
| Cash & equivalents | $180.1M | $288.3M | $453.9M | $112.5M | $144.5M |
| Accounts receivable | $552.4M | $473.6M | $457.4M | $400.6M | $368.3M |
| Inventory | $377.8M | $381.9M | $380.3M | $367.8M | $269.0M |
| Other current assets | $303.6M | $256.2M | $203.6M | $220.5M | $173.8M |
| Property, plant & equipment | $747.4M | $713.1M | $702.2M | $649.5M | $587.7M |
| Goodwill | $414.0M | $405.1M | $366.0M | $361.8M | $359.3M |
| Intangible assets | $109.8M | $111.7M | $84.5M | $97.7M | $99.0M |
| Other non-current assets | $542.5M | $547.5M | $496.5M | $417.7M | $330.4M |
| Accounts payable | $110.4M | $114.2M | $110.6M | $110.2M | $116.1M |
| Accrued liabilities | $530.1M | $502.1M | $478.7M | $433.7M | $458.9M |
| Deferred revenue (current) | $35.3M | $33.8M | $37.2M | $37.9M | $40.0M |
| Short-term debt | $75.0M | $167.8M | $75.0M | $75.0M | $75.0M |
| Long-term debt | $374.8M | $449.8M | $622.9M | $694.4M | $775.2M |
| Other non-current liabilities | $56.5M | $44.3M | $65.5M | $67.6M | $70.9M |
| Common stock & paid-in capital | $10.8M | $10.8M | $10.8M | $10.7M | $10.7M |
| Retained earnings | $6.39B | $5.33B | $4.44B | $3.60B | $2.92B |
| Accumulated other comprehensive income (loss) | -$68.8M | -$93.6M | -$71.2M | -$77.8M | -$53.5M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $1.18B | $929.0M | $906.5M | $543.0M | $755.5M |
| Investing cash flow | -$136.2M | -$207.1M | -$125.3M | -$195.3M | -$293.0M |
| Financing cash flow | -$1.16B | -$878.1M | -$442.0M | -$370.9M | -$697.4M |
| Free cash flow | $1.06B | $808.1M | $772.9M | $394.1M | $636.0M |
| Capital expenditures | $124.7M | $120.9M | $133.6M | $148.8M | $119.5M |
| Depreciation & amortization | $145.2M | $129.9M | $114.9M | $111.9M | $104.6M |
| Share-based compensation | $60.0M | $60.3M | $59.7M | $49.8M | $37.8M |
| Deferred income taxes | $131.2M | -$24.2M | -$48.3M | -$34.9M | -$3.4M |
| Change in accounts receivable | $68.7M | $28.3M | $53.9M | $41.4M | $33.1M |
| Change in inventory | $789.0K | $28.0M | $28.7M | $121.7M | $52.9M |
| Change in accounts payable | -$8.6M | $8.1M | -$557.0K | $3.5M | — |
| Purchases of investments | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — |
| Share repurchases | $1.22B | $837.0M | $71.9M | $819.7M | $746.8M |
| Tax withholding on stock comp | $7.2M | $10.5M | $10.0M | $10.6M | $15.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IDXX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-17 to 2026-09-04
Recent transactions
- Insiders have net sold 2,203 shares over the last 182 days, across 0 purchases and 1 sale.
- Most recent: Kingsley Lawrence D (Director) — Option exercise of 2,203 shares on 2026-09-04.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)2,203 sh(1 txns)
Net Shares-2,203
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kingsley Lawrence D | Director | Option exercise | 2026-09-04 | 2,203 |
| Emerson Andrew | EVP, CFO and Treasurer | Option exercise | 2026-08-20 | 265 |
| HOOLEY JOSEPH L | Director | Grant / award | 2026-07-30 | 49 |
| FENNELL GEORGE | Executive Vice President | Option exercise | 2026-06-01 | 639 |
| Vandebroek Sophie V. | Director | Option exercise | 2026-05-07 | 257 |
| SZOSTAK M ANNE | Director | Option exercise | 2026-05-07 | 257 |
| Peacock Karen | Director | Option exercise | 2026-05-07 | 101 |
| JUNIUS DANIEL M | Director | Option exercise | 2026-05-07 | 257 |
| Underberg Sharon E. | EVP, GC & Corporate Secretary | Option exercise | 2026-03-03 | 197 |
| Hunt Nimrata | Executive Vice President | Open market sale | 2026-03-03 | 1,758 |
| MAZELSKY JONATHAN JAY | President and CEO | Option exercise | 2026-02-27 | 197 |
| Erickson Michael G | Executive Vice President | Option exercise | 2026-02-19 | 719 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-04 | Kingsley Lawrence D | Director | Option exercise | 2,203 | $114.17 |
| 2026-09-04 | Kingsley Lawrence D | Director | Open market sale | 2,203 | $532.08 |
| 2026-08-20 | Emerson Andrew | EVP, CFO and Treasurer | Option exercise | 265 | $178.26 |
| 2026-08-20 | Emerson Andrew | EVP, CFO and Treasurer | Tax withholding | 86 | $0.00 |
| 2026-07-30 | HOOLEY JOSEPH L | Director | Grant / award | 49 | $558.80 |
| 2026-06-01 | FENNELL GEORGE | Executive Vice President | Option exercise | 639 | $0.00 |
| 2026-06-01 | FENNELL GEORGE | Executive Vice President | Tax withholding | 284 | $566.79 |
| 2026-05-07 | Vandebroek Sophie V. | Director | Option exercise | 257 | $0.00 |
| 2026-05-07 | SZOSTAK M ANNE | Director | Option exercise | 257 | $0.00 |
| 2026-05-07 | Peacock Karen | Director | Option exercise | 101 | $0.00 |
| 2026-05-07 | Kingsley Lawrence D | Director | Option exercise | 257 | $0.00 |
| 2026-05-07 | Kingsley Lawrence D | Director | Option exercise | 82 | $0.00 |
| 2026-05-07 | JUNIUS DANIEL M | Director | Option exercise | 257 | $0.00 |
| 2026-05-07 | HOOLEY JOSEPH L | Director | Option exercise | 158 | $0.00 |
| 2026-04-30 | HOOLEY JOSEPH L | Director | Grant / award | 43 | $560.80 |
| 2026-03-03 | Underberg Sharon E. | EVP, GC & Corporate Secretary | Option exercise | 197 | $505.53 |
| 2026-03-03 | Hunt Nimrata | Executive Vice President | Open market sale | 1,758 | $634.57 |
| 2026-02-27 | MAZELSKY JONATHAN JAY | President and CEO | Option exercise | 197 | $505.53 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Option exercise | 23,326 | $141.60 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,281 | $650.67 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,095 | $651.49 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,669 | $652.49 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,171 | $653.68 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,111 | $654.63 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,488 | $655.85 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,343 | $656.85 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 2,860 | $657.84 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 3,660 | $658.92 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 2,859 | $659.75 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,200 | $661.10 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 1,000 | $662.16 |
| 2026-02-26 | MAZELSKY JONATHAN JAY | President and CEO | Open market sale | 2,589 | $663.04 |
| 2026-02-26 | Hunt Nimrata | Executive Vice President | Open market sale | 2,693 | $661.54 |
| 2026-02-19 | Erickson Michael G | Executive Vice President | Option exercise | 719 | $141.60 |
| 2026-02-19 | Erickson Michael G | Executive Vice President | Option exercise | 817 | $178.26 |
| 2026-02-19 | Erickson Michael G | Executive Vice President | Option exercise | 483 | $206.94 |
| 2026-02-19 | Erickson Michael G | Executive Vice President | Option exercise | 183 | $544.08 |
| 2026-02-19 | Erickson Michael G | Executive Vice President | Option exercise | 197 | $505.53 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Option exercise | 1,191 | $141.60 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Option exercise | 4,180 | $178.26 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Open market sale | 456 | $623.76 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Open market sale | 204 | $625.24 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Open market sale | 1,288 | $626.26 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Open market sale | 2,694 | $628.22 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Open market sale | 689 | $629.09 |
| 2026-02-17 | Erickson Michael G | Executive Vice President | Open market sale | 40 | $629.86 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-11-02 21:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-11-02 | 10-Q | 2026-09-30 | View on SEC.gov → |
| 2026-11-02 | 8-K | 2026-11-02 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-08-24 | 4 | 2026-08-20 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-07-30 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-12 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-12 | View on SEC.gov → |
| 2026-05-14 | 4 | 2026-05-12 | View on SEC.gov → |
Recent news
Headlines about IDXX (IDEXX Laboratories, Inc.). Links open the publisher — we don’t host full articles.
-
IDEXX Laboratories surges 22% on Q3 beat, raised outlook
Seeking Alpha · 2026-11-02 -
IDEXX Laboratories surges 22% on Q3 beat, raised outlook (IDXX:NASDAQ)
Seeking Alpha · 2026-11-02 -
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
MarketWatch · 2026-11-02 -
Revenue tops $1.2B at IDEXX (IDXX), while quarterly earnings climb from $3.40 a share.
Stock Titan · 2026-11-02 -
US Equity Markets Mixed as Technology Sell-Off Continues, Crude Oil Prices Dip
Yahoo · 2026-11-02 -
Idexx Labs Barks Up A Third-Quarter Beat, And Fetches Its Next Bullish Move
Yahoo Finance · 2026-11-02 -
IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook, Record ...
Yahoo · 2026-11-02 -
Sector Update: Healthcare Stocks Ease Late Afternoon
Yahoo · 2026-11-02
No headlines in this category right now — try “All”.